iShares Biotechnology ETF
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.36% less ownership
Funds ownership: 70.93% [Q4 2024] → 68.57% (-2.36%) [Q1 2025]
5% less funds holding
Funds holding: 863 [Q4 2024] → 818 (-45) [Q1 2025]
13% less capital invested
Capital invested by funds: $4.59B [Q4 2024] → $3.97B (-$618M) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 8 (-3) [Q1 2025]
37% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 76
45% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 353
54% less call options, than puts
Call options by funds: $293M | Put options by funds: $630M
Research analyst outlook
We haven’t received any recent analyst ratings for IBB.
Financial journalist opinion
Based on 6 articles about IBB published over the past 30 days
Neutral
The Street
1 day ago
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Negative
Investors Business Daily
2 days ago
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon."
Neutral
Seeking Alpha
4 days ago
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar objective, and are over-diversified. For reasons I explain here.
Positive
Seeking Alpha
5 days ago
5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs
The Big Beautiful Bill boosts defense, industrials, and manufacturing, but healthcare and some REITs face headwinds from Medicaid cuts and policy shifts. AI optimism and the new legislation are fueling a broad market rally, but I question if AI stocks are outpacing their earnings, signaling a potential bubble. The Magnificent 7 era is over; META, MSFT, NVDA, and AMZN are the new leaders, while AAPL, GOOG, and TSLA face unique challenges in the AI race.
Neutral
Zacks Investment Research
3 weeks ago
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
The iShares Biotechnology ETF (IBB) made its debut on 02/05/2001, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Neutral
CNBC Television
3 weeks ago
Fast Money: WTI, IBB, UBER, CAT
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
Positive
See It Market
1 month ago
Biotechnology Sector ETF (IBB) Nears Important Pivot Point
As of the latest data available, the top three holdings in the iShares Biotechnology ETF (NASDAQ: IBB) are: These three companies collectively represent approximately 25.68% of the Biotechnology Sector ETF's total assets. With GILD in top technical position, AMGN and VRTX are also looking interesting.
Neutral
Seeking Alpha
1 month ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
Seeking Alpha
1 month ago
IBB: Now Is The Time To Be Contrarian
Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks, the innovative pipeline, and AI-driven process improvements suggests the market may be missing the big picture. Institutional investors are getting back in on the action, evident from the strong Q1 in terms of deal activity.
Charts implemented using Lightweight Charts™